论文部分内容阅读
目的观察甘氨双唑钠增敏后程加速超分割协同化疗治疗食管癌的近期疗效,研究和探讨放(化)疗增敏剂、化疗药物、放疗剂量分割方式及三者联合应用的机制。方法 将60例病理证实、各期、未进行过任何治疗的食管癌患者随机分为甘氨双唑钠增敏后程加速超分割放疗结合化疗的试验组(LCAHR+C+CMNa)和单纯后程加速超分割放疗结合化疗的对照组(LCAHR+C),分别采用上述两种方法治疗,在治疗前、治疗第4周和治疗后分别行CT或X线片检查,根据摄片进行肿瘤大小的测量,比较两种方法治疗肿瘤的近期疗效。结果 对照组有效22例,无效8例;试验组有效28例,无效2例,试验组近期疗效优于对照组(P<0.05),两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论 用甘氨双唑钠增敏后程加速超分割协同化疗的方法治疗食管癌近期疗效显著,不良反应可以耐受。
Objective To observe the short-term curative effect of glycopyrrolate sodium-sensitized late course accelerated hyperfractionated chemotherapy in the treatment of esophageal cancer and to study and discuss the mechanism of radiosensitizer, chemotherapeutic drugs, dose division of radiotherapy and their combined application. Methods Sixty patients with pathologically confirmed esophageal cancer who had not undergone any treatment were randomly divided into experimental group (LCAHR + C + CMNa) with accelerated course of hyperglycemia followed by chemotherapy of glycopyrrolate sodium, Accelerated hyperfractionated radiotherapy combined with chemotherapy in the control group (LCAHR + C), respectively, using the two methods of treatment, before treatment, the first 4 weeks and after treatment, respectively, CT or X-ray examination, according to radiography tumor size Of the measurements, comparing the two methods of treatment of cancer in the near future. Results The control group was effective in 22 cases and ineffective in 8 cases. The experimental group was effective in 28 cases and the ineffective in 2 cases. The curative effect in the experimental group was better than that in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusions The treatment of esophageal cancer with glycopyrrolate late course accelerated hyperfractionated chemo-synchrocherapy has a significant short-term curative effect and adverse reactions can be tolerated.